NCT02397889View on ClinicalTrials.gov

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 18, 2015

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
DRUG

Ketamine

This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).

DRUG

Midazolam

This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).

Trial Locations (1)

10029

Depression and Anxiety Center (DAC), New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT02397889 - Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD) | Biotech Hunter | Biotech Hunter